← Back to patent-cliff list
Redasemtide
Tier C — Watch / tradeRedasemtide
Stemrim
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Not applicable
Indications (approved)：大疱性表皮松解症, Stroke, Ischaemic stroke
Regional status
US
Phase II
2023-07-14
EU
Phase II
2023-07-14
China
Phase II
2023-07-14
Japan
Phase II
2023-07-14
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Redasemtide?
Approved indications include: 大疱性表皮松解症, Stroke, Ischaemic stroke.
When does the Redasemtide patent expire?
No public expiry year is available for Redasemtide yet; this page updates once verified.
How do I get a quote for Redasemtide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21